OBJECTIVES: To perform a pharmacoeconomic evaluation of Evra in Mexico from the perspective of insurance companies METHODS: We used a Markov analytical model to assess costs and benefits associated with the use of Evra in quinquennial age-groups Mexican women covered by a private health insurance. Comparator for Evra was oral contraceptives (OC’s). Effectiveness measure was the number of pregnancies averted per 100 users. These values were estimated by expert panel consensus based on pregnancy probabilities for hormonal contraceptive methods taken from the 2006 National Demography Survey and literature review. Contraceptive methods costs were calculated using the market prices, while mean values of medical reimbursement tabulator were used as proxy of pregnancy costs and adjusted to 2009 values. We assumed a 3-years intergenesic interval for base-case evaluation; however through one-way sensitivity analyses we knew the impact of varying the intergenesic interval from one year to five years, using a 5% discount rate. Probabilistic sensitivity analyses via Monte Carlo simulations were undertaken to incorporate likely distributional properties of key model parameters. RESULTS: Base-case results showed Evra as the dominant strategy, obtaining savings in a range of €4840 for ages 30–34 until €7454 for ages 25–29, being contraceptive method the main cost driver for both options. Also Evra enable to prevent between 10 and 14 additional pregnancies compared against OC’s. From one-way sensitivity analysis cost-savings exhibited a growing pattern until year 3, and a decreasing trend towards year 5. These results were consistent for all cohorts, however certain differences were observed between 15-19 and 25-29 age-groups at year 1. CONCLUSIONS: Compared with OC’s, Evra represents a more effective and less costly contraceptive method for Mexican women.